By Fineline Cube Impact Therapeutics (HKG: 7630) presented updated Phase I/II clinical data for IMP1734 (EIK1003), a highly selective PARP1 inhibitor, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The trial evaluated IMP1734 as monotherapy and in combination with paclitaxel in patients with advanced solid tumors, demonstrating enhanced efficacy in the combination arm with an overall objective response rate (ORR) of 24.5%, including 29.6% ORR in epithelial ovarian cancer and 19.2% ORR in HER2-negative breast cancer. The monotherapy cohort showed 14.3% ORR with a median duration of response of 7.8 months.
Clinical Trial Results
Monotherapy Cohort (Cohort 1A)
| Parameter | Result |
|---|---|
| Evaluable Patients | 49 |
| Objective Response Rate (ORR) | 14.3% (all partial responses) |
| Disease Control Rate (DCR) | 38.8% |
| Median Duration of Response (DOR) | 7.8 months |
| Safety Profile | Manageable |
Combination Cohort (Cohort 1C: IMP1734 + Paclitaxel)
| Parameter | Overall | Epithelial Ovarian Cancer | HER2-Negative Breast Cancer |
|---|---|---|---|
| Evaluable Patients | 53 | Subset analysis | Subset analysis |
| Objective Response Rate (ORR) | 24.5% | 29.6% | 19.2% |
| Response Types | 1 CR + 12 PRs | Not specified | Not specified |
| Safety Profile | Manageable | Consistent across subgroups | Consistent across subgroups |
Drug Profile & Mechanism of Action
- Molecule: IMP1734 (EIK1003) – highly selective PARP1 inhibitor
- Selectivity Advantage: Enhanced specificity for PARP1 over PARP2 may reduce hematological toxicity compared to pan-PARP inhibitors
- Development Strategy: Evaluated both as monotherapy and in combination with standard chemotherapy (paclitaxel)
- Target Population: Advanced solid tumors, with particular focus on epithelial ovarian cancer and HER2-negative breast cancer
- Clinical Rationale: PARP inhibition exploits DNA repair deficiencies in homologous recombination-deficient tumors
Strategic Clinical Implications
The updated data reveals several key insights for PARP inhibitor development:
- Combination Superiority: IMP1734 + paclitaxel demonstrates 71% higher ORR (24.5% vs 14.3%) compared to monotherapy
- Ovarian Cancer Focus: 29.6% ORR in epithelial ovarian cancer represents competitive efficacy in a high-need indication
- Breast Cancer Activity: 19.2% ORR in HER2-negative breast cancer expands potential beyond traditional PARP inhibitor indications
- Durability: 7.8-month median DOR in monotherapy responders indicates meaningful clinical benefit
- Complete Response: Achievement of 1 confirmed CR in combination cohort suggests potential for deeper responses
“This updated Phase I/II data demonstrates that IMP1734’s highly selective PARP1 inhibition translates into meaningful clinical activity across multiple tumor types,” said Dr. Chen Wei, Chief Executive Officer of Impact Therapeutics. “The enhanced efficacy observed with paclitaxel combination, particularly in ovarian cancer, provides a strong foundation for our ongoing development strategy.”
Competitive Landscape & Market Opportunity
The results position IMP1734 to compete in the evolving PARP inhibitor market:
- Differentiation Strategy: High PARP1 selectivity may offer improved safety profile compared to approved pan-PARP inhibitors (olaparib, niraparib, rucaparib)
- Market Expansion: Activity in HER2-negative breast cancer beyond BRCA-mutated populations could broaden addressable market
- Combination Potential: Synergy with taxanes supports development in front-line and later-line settings
- Global Opportunity: Data supports international regulatory filings and partnership discussions
Industry analysts estimate the global PARP inhibitor market will reach $4–6 billion annually by 2028, with selective inhibitors potentially capturing premium positioning if they demonstrate superior safety profiles while maintaining efficacy.
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory pathways, and market opportunities for IMP1734. Actual results may differ due to clinical trial outcomes, regulatory decisions, and competitive dynamics.-Fineline Info & Tech